Gene therapy slows vision loss in stargardt disease trial

NCT ID NCT05956626

Ongoing Disease control Sponsor: Ocugen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study tests a new gene therapy called OCU410ST for people with Stargardt disease, an inherited eye condition that causes vision loss. Early results show the treatment slowed damage to the retina by nearly half and improved or stabilized eyesight in all treated patients. The trial now enrolls 51 participants aged 5 and older to confirm these benefits and check safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ABCA4-RELATED RETINOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ABCA4-related retinopathy Stargardt disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STARGARDT DISEASE

Contacts and locations

Locations

Advanced Research, LLC

Pompano Beach, Florida, 33064, United States
Associated Retina Consultants

Phoenix, Arizona, 85020, United States
Bascom Palmer Eye Institute

Miami, Florida, 33136, United States
Boston Children's Hospital

Boston, Massachusetts, 02115, United States
Duke Eye Center

Durham, North Carolina, 27710, United States
Erie Retina Research, LLC

Erie, Pennsylvania, 16505, United States
Mississippi Retina Associates

Jackson, Mississippi, 39202, United States
Retina Consultants of Texas

Bellaire, Texas, 77401, United States
Retina Foundation of the Southwest

Dallas, Texas, 75231, United States
Retina Partners Midwest, P.C.

Carmel, Indiana, 46032, United States
Retinal Consultants Medical Group

Sacramento, California, 95825, United States
The Retina Institute

St Louis, Missouri, 63128, United States
Valley Retina Institute

McAllen, Texas, 78503, United States
Vitreo Retinal Associates, P.A.

Gainesville, Florida, 32607, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.